Bliss GVS Pharma (506197) Q1 26/27 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a review by the Audit Committee and statutory auditors.

• Financials prepared in accordance with Ind AS and reviewed with unmodified conclusion by auditors.

• Board also approved a postal ballot notice for the appointment of a new Non-Executive Non-Independent Director.

Financial highlights

• Consolidated revenue from operations for the quarter ended June 30, 2026, was ₹28,557.56 lakh, up from ₹25,699.32 lakh in the previous quarter and ₹20,746.92 lakh year-over-year.

• Consolidated net profit for the quarter was ₹4,303.79 lakh, compared to ₹4,492.33 lakh in the previous quarter and ₹3,557.51 lakh year-over-year.

• Total comprehensive income for the quarter was ₹4,889.00 lakh, compared to ₹4,791.80 lakh in the previous quarter and ₹3,313.42 lakh year-over-year.

• Basic and diluted EPS for the quarter were ₹4.08 and ₹4.04, respectively.

Outlook and guidance

• No explicit forward-looking guidance provided, but continued focus on pharmaceutical and healthcare segment indicated.